|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Neuromed Pharmaceuticals |
| Information provided by: | Neuromed Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00631319 |
Purpose
To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain
| Condition | Intervention | Phase |
|
Chronic Pain |
Drug: OROS Hydromorphone |
Phase III |
| MedlinePlus related topics: | Osteoarthritis |
| ChemIDplus related topics: | Hydromorphone Hydromorphone hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment |
| Official Title: | A Phase III, Flexible Dose Titration Follwed by a Randomized Double-Blind Study of Controlled Release OROS Hydromorphone HCL Compared to Placebo in Patients With Chronic OA Pain |
| Estimated Enrollment: | 400 |
| Study Start Date: | February 2008 |
| Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Eligibility
| Ages Eligible for Study: | 30 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Tracey L Johnson | 484.533.6916 | tjohnson@neuromed.com |
| Contact: Carole Hodge | hodgecarole@praintl.com |
| United States, Pennsylvania | |||||
| Tracey Johnson | Recruiting | ||||
| Philadelephia, Pennsylvania, United States | |||||
| Contact: Tracey johnson 484-533-6916 tjohnson@neuromed.com | |||||
| Neuromed Pharmaceuticals |
More Information
sponsor home page 
  |
| Responsible Party: | Neuromed Pharmaceuticals ( Neuromed Pharmaceuticals ) |
| Study ID Numbers: | NMT 1077-302 |
| First Received: | February 28, 2008 |
| Last Updated: | July 30, 2008 |
| ClinicalTrials.gov Identifier: | NCT00631319 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|